Editas Medicine reports advancements in in vivo gene editing, financial results, and plans for upcoming development candidates by mid-2025. Editas Medicine, Inc. announced its progress in developing ...
Cibus, Inc. announced significant advancements in its gene editing technology, particularly the establishment of production standards for its proprietary RTDS gene editing system, which enables the ...
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
EDIT-401 is an experimental, potentially transformative in vivo gene editing medicine, based on Editas’ differentiated upregulation approach. EDIT-401 is designed to treat hyperlipidemia by directly ...
In addition to my other work, I also freelance as a developmental editor. You can read more about what developmental editing is and what services I offer on my ...
Scientists at the University of California, Santa Cruz (UCSC), used CRISPR to engineer cellular models of embryos that mimic what happens in the first few days after reproductive cells meet. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results